[go: up one dir, main page]

AR016436A1 - Proteina que inhibe a la p27, adn que la codifica, anticuerpos y productos de disociacion de los mismos, acido nucleico antisentido, estructura artificialde acido nucleico y la utilizacion de todo esto en terapia y profilaxis de enfermedades - Google Patents

Proteina que inhibe a la p27, adn que la codifica, anticuerpos y productos de disociacion de los mismos, acido nucleico antisentido, estructura artificialde acido nucleico y la utilizacion de todo esto en terapia y profilaxis de enfermedades

Info

Publication number
AR016436A1
AR016436A1 ARP980106444A ARP980106444A AR016436A1 AR 016436 A1 AR016436 A1 AR 016436A1 AR P980106444 A ARP980106444 A AR P980106444A AR P980106444 A ARP980106444 A AR P980106444A AR 016436 A1 AR016436 A1 AR 016436A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
antibodies
protein
therapy
prophylaxis
Prior art date
Application number
ARP980106444A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR016436A1 publication Critical patent/AR016436A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)

Abstract

Proteína que inhibe a la proteína celular p27 y con ello suprime la inhibicion de la proliferacion de la célula, producida por la p27, mutantes de ésta concarácter en parte interferente dominante, los correspondientes ácidos nucleicos que la codifican, anticuerpos y productos de disociacion de estos y lautilizacion de proteínas, ácidos nucleicos y anticuerpos para la profilaxis y la terapia de enfermedades; estructura artificial de ácido nucleico para laterapia génica de enfermedades, que contiene los ácidos nucleicos antes mencionados y su utilizacion para la estimulacion y proliferacion de células.
ARP980106444A 1997-12-20 1998-12-17 Proteina que inhibe a la p27, adn que la codifica, anticuerpos y productos de disociacion de los mismos, acido nucleico antisentido, estructura artificialde acido nucleico y la utilizacion de todo esto en terapia y profilaxis de enfermedades AR016436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19756975A DE19756975A1 (de) 1997-12-20 1997-12-20 Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie einer Erkrankung

Publications (1)

Publication Number Publication Date
AR016436A1 true AR016436A1 (es) 2001-07-04

Family

ID=7852804

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980106444A AR016436A1 (es) 1997-12-20 1998-12-17 Proteina que inhibe a la p27, adn que la codifica, anticuerpos y productos de disociacion de los mismos, acido nucleico antisentido, estructura artificialde acido nucleico y la utilizacion de todo esto en terapia y profilaxis de enfermedades
ARP980106445A AR017887A1 (es) 1997-12-20 1998-12-17 Estructuras artificiales de acidos nucleicos, procedimiento para su preparacion, celula aislada y uso de dichas estructuras y dicha celula para lamanufactura de un medicamento

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP980106445A AR017887A1 (es) 1997-12-20 1998-12-17 Estructuras artificiales de acidos nucleicos, procedimiento para su preparacion, celula aislada y uso de dichas estructuras y dicha celula para lamanufactura de un medicamento

Country Status (15)

Country Link
US (1) US6265562B1 (es)
EP (2) EP0926237A3 (es)
JP (2) JPH11313686A (es)
KR (2) KR19990063284A (es)
CN (2) CN1227871A (es)
AR (2) AR016436A1 (es)
AU (2) AU758030B2 (es)
BR (2) BR9805151A (es)
CA (2) CA2255141A1 (es)
CZ (2) CZ422598A3 (es)
DE (1) DE19756975A1 (es)
HU (1) HUP9802961A3 (es)
ID (2) ID21582A (es)
PL (2) PL330452A1 (es)
TR (2) TR199802649A3 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19751587A1 (de) 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme
GB9727512D0 (en) * 1997-12-31 1998-02-25 Adprotech Plc Fuzzy genes and their application in molecular adjuvants
DE19831420A1 (de) * 1998-07-14 2000-01-20 Hoechst Marion Roussel De Gmbh Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
GB0025229D0 (en) * 2000-10-14 2000-11-29 Adprotech Ltd Veterinary immunisation vectors
US20030113784A1 (en) * 2001-11-29 2003-06-19 Jaime Flores-Riveros Regulated expression of recombinant DNA
JP5976986B2 (ja) * 2005-10-01 2016-08-24 チャールズ スタウト， 調節可能な融合プロモーター
SI2147105T1 (sl) 2007-05-02 2013-08-30 Merial Limited DNA-plazmidi z izboljšano ekspresijo in stabilnostjo
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
KR20190095502A (ko) * 2017-01-03 2019-08-14 바이오아트라, 엘엘씨 노화 세포 치료를 위한 단백질 치료제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
DE19524720A1 (de) 1995-07-12 1997-01-16 Hoechst Ag Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3"
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
DE19605274A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
DE19751587A1 (de) * 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme

Also Published As

Publication number Publication date
AR017887A1 (es) 2001-10-24
CN1227871A (zh) 1999-09-08
ID21534A (id) 1999-06-24
AU747246B2 (en) 2002-05-09
KR19990063284A (ko) 1999-07-26
JPH11313686A (ja) 1999-11-16
EP0926237A2 (de) 1999-06-30
HU9802961D0 (en) 1999-02-01
EP0926237A3 (de) 2000-01-05
TR199802649A2 (xx) 1999-07-21
CZ422398A3 (cs) 1999-07-14
CZ422598A3 (cs) 1999-07-14
PL330451A1 (en) 1999-06-21
TR199802649A3 (tr) 1999-07-21
ID21582A (id) 1999-06-24
AU758030B2 (en) 2003-03-13
KR19990063285A (ko) 1999-07-26
TR199802648A3 (tr) 1999-07-21
BR9805152A (pt) 2000-03-21
TR199802648A2 (xx) 1999-07-21
BR9805151A (pt) 2000-03-21
DE19756975A1 (de) 1999-06-24
AU9720598A (en) 1999-07-08
HUP9802961A3 (en) 2000-04-28
US6265562B1 (en) 2001-07-24
CN1225367A (zh) 1999-08-11
JPH11308997A (ja) 1999-11-09
PL330452A1 (en) 1999-06-21
EP0926236A1 (de) 1999-06-30
HUP9802961A2 (hu) 1999-07-28
CA2255141A1 (en) 1999-06-20
CA2255143A1 (en) 1999-06-20
AU9720498A (en) 1999-07-08

Similar Documents

Publication Publication Date Title
AR016436A1 (es) Proteina que inhibe a la p27, adn que la codifica, anticuerpos y productos de disociacion de los mismos, acido nucleico antisentido, estructura artificialde acido nucleico y la utilizacion de todo esto en terapia y profilaxis de enfermedades
DE69637874D1 (de) C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NZ513153A (en) Selection of proteins using RNA-protein fusions
DE3885214D1 (de) Verfahren zur Isolierung basischer Proteine aus Proteingemischen.
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
CY1112195T1 (el) Μεθοδος παρασκευης ενος πεπτιδιου με pl πανω απο 8 ή κατω απο 5
NO995458D0 (no) Humane 12-lignende reseptorproteiner, beslektede reagenser og metoder
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
EP1131333A4 (en) INSULATED NUCLEIC ACID MOLECULES ENCODING INDUCIBLE FACTORS DERIVED FROM T-CELL (TIF), ENCODED PROTEINS AND USE THEREOF
MEP32808A (en) Osteoprotegerin binding proteins and receptors
EP1009814A4 (en) KDR, A HUMAN TYROSIN KINASE RECEPTOR
ES2133813T3 (es) Cadenas de lamininas: diagnostico y uso terapeutico.
ATE449850T1 (de) Mutanten von flt3-l und ihre verwendungen
AU6160201A (en) Human polypeptides causing or leading to the killing of cells including lymphoidtumor cells
AR026946A1 (es) Osteoprotegerina/receptores de factores de necrosis de tumores
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
IL145689A0 (en) Methods
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
DK1082423T3 (da) Cyclin E2-gener og -proteiner
ES2059436T3 (es) Proteina de la membrana exterior f de pseudomonas aeruginosa.
NO972063L (no) Isolert BMP-reseptorkinaseprotein, DNA-sekvens, rekombinant ekspresjonsvektor samt vertscelle
ATE470716T1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
ES2045004T3 (es) Procedimiento para la preparacion de proteinas extra\as en estreptomicetos.
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe

Legal Events

Date Code Title Description
FB Suspension of granting procedure